The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials

Abstract Regulatory T cell (Treg) impairment is implicated in the pathogenesis of chronic inflammatory diseases, but relatively little is known about the therapeutic potential of Treg restoration. Here we present clinical evidence for the Treg-selective interleukin-2 receptor agonist rezpegaldesleuk...

Full description

Bibliographic Details

Main Authors:	Jonathan I. Silverberg, David Rosmarin, Raj Chovatiya, Thomas Bieber, Stephen Schleicher, Lisa Beck, Melinda Gooderham, Sohail Chaudhry, Christie Fanton, Danni Yu, Joshua Levy, Yi Liu, Takahiro Miyazaki, Mary Tagliaferri, Carsten Schmitz, Ajay Nirula, Brian Kotzin, Jonathan Zalevsky
Format:	Artigo
Language:	Inglês
Published:	Nature Portfolio 2024-10-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-024-53384-1
Tags:	Add Tag No Tags, Be the first to tag this record!